Select Page

PRESTIGE AF is a €6.9m project, aimed at patients with atrial fibrillation (AF), a common heart condition which causes irregular and abnormally fast heartbeat, who have previously had a stroke caused by bleeding in the brain (termed intracerebral haemorrhage or ICH). The Prevention of Stroke in intracerebral hemorrhage survivor with Atrial Fibrillation (PRESTIGE-AF) brings together scientists and clinicians across Europe with the goal of reducing the risk of further stroke in this group of patients.

At the core of the PRESTIGE-AF project is a clinical trial to gather evidence around recommended medication for stroke prevention in patients with AF. Several sub-studies will explore individual predictive risk modelling using brain imaging, genetic testing and other biological markers. Other aspects of the project include exploring cognitive and psychological factors and drug adherence by patients.

Please read next:  Survivors, carers and therapists – would you use technology to help rehab? We want to know!

Congratulations to the team at Imperial College Healthcare NHS Trust (UK) who randomised the first participant into the PRESTIGE-AF Study, while other sites across Europe are underway to do the same.

The team at Imperial College Healthcare NHS Trust who randomised the first participant. From left: Vaishali Dave, Peter Wilding, Ana Gil, Sheila Mashate (front-right). Congratulations to the team!

 

The Stroke Alliance for Europe (SAFE) has responsibility in the project for disseminating information about TENSION to the stroke community. For more information, please contact research@safestroke.eu.

PRESTIGE-AF has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754517.